Asparagine synthetase (glutamine-hydrolyzing) messenger RNA (ASNS mRNA)

Asparagine synthetase (ASNS) mRNA is the transcript that encodes the enzyme responsible for the de novo synthesis of L-asparagine from aspartate and glutamine. In many malignancies, such as acute lymphoblastic leukemia (ALL) and various solid tumors, cells exhibit a dependency on exogenous asparagine; however, they often upregulate ASNS mRNA expression as a survival mechanism when extracellular asparagine is depleted by therapies like L-asparaginase. This adaptive upregulation makes ASNS mRNA a high-priority therapeutic target for silencing strategies, including antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), which aim to restore sensitivity to asparagine deprivation. Beyond its role in oncology, mutations in the ASNS gene that affect mRNA stability or protein function lead to asparagine synthetase deficiency (ASNSD), a severe neurological disorder characterized by microcephaly and intractable seizures. Because the brain relies heavily on endogenous asparagine synthesis due to the blood-brain barrier's limited permeability to the amino acid, therapeutic targeting of ASNS mRNA must carefully consider potential neurotoxic side effects. Current research focuses on optimizing the delivery and specificity of these RNA-targeting agents to maximize anti-tumor efficacy while minimizing systemic toxicity.

Other names

ASNS transcriptAsparagine synthetase mRNATS11 mRNACell cycle-regulated gene 2 mRNA

RNA interference (RNAi) or antisense-mediated degradation of ASNS mRNA to prevent the translation of the asparagine synthetase enzyme, thereby inhibiting intracellular asparagine production.